Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05664074 · ClinicalTrials.gov registry record · Phase 4
Rectal Indomethacin vs Intravenous Ketorolac
A Phase 4 study, sponsored by David Vitale MD.
- Completed
- Registry status
- Phase 4
- Development phase
- 192
- Enrollment target
NCT05664074 is a Phase 4 study that has completed, run by David Vitale MD. The registered enrollment target is 192 participants.
The verdict
NCT05664074, a Phase 4 study, has completed, sponsored by David Vitale MD.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 192 participants
- Enrollment target
Study Summary
Endoscopic retrograde cholangiopancreatography (ERCP) is an essential procedure that can be complicated by post-ERCP pancreatitis (PEP). Indomethacin and ketorolac are two medications used to prevent PEP. The main reason for this research study is to compare the effectiveness these drugs at reducing rates of PEP. There have been no studies comparing the effectiveness of these medications in preventing PEP in pediatric patients. You are being asked to take part in this research study because you are scheduled to have an ERCP as part of your medical care.
Interventions
- DRUG IV ketorolac
- DRUG Rectal indomethacin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2022-11-07 |
| Est. Completion | 2025-02-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05664074
The ClinicalTrials.gov registry entry for NCT05664074 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 192 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is David Vitale MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which IV ketorolac is the first listed.
NCT05664074 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05664074 about?
NCT05664074 is a clinical study titled "Rectal Indomethacin vs Intravenous Ketorolac". Endoscopic retrograde cholangiopancreatography (ERCP) is an essential procedure that can be complicated by post-ERCP pancreatitis (PEP). Indomethacin and ketorolac are two medications used to prevent PEP. The main reason for this research study is to compare the effectiveness these drugs at reducing...
What is the current status of trial NCT05664074?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 192 participants. The study started on 2022-11-07. Estimated completion is 2025-02-05.
What interventions are being tested in trial NCT05664074?
The interventions under investigation include: IV ketorolac (DRUG), Rectal indomethacin (DRUG).
Who is sponsoring clinical trial NCT05664074?
This trial is sponsored by David Vitale MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.